Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High Risk Essential Thrombocythemia”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00005641
What this trial is testing

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+2 more
H. Lee Moffitt Cancer Center and Research Institute
Large-scale testing (Phase 3)Study completedNCT01259856
What this trial is testing

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Who this might be right for
High Risk Polycythemia VeraHigh Risk Essential Thrombocythemia
Ronald Hoffman 168
Not applicableLooking for participantsNCT07362225
What this trial is testing

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

Who this might be right for
Polycythemia VeraET (Essential Thrombocythemia)Polycythemia Vera (PV)+52 more
MPN Research Foundation 5,000
Early research (Phase 1)Looking for participantsNCT06343805
What this trial is testing

LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Who this might be right for
Primary Myelofibrosis
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company 256
Large-scale testing (Phase 3)Study completedNCT03952039
What this trial is testing

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Who this might be right for
Primary MyelofibrosisPost-Polycythemia VeraMyelofibrosis
Celgene 202
Large-scale testing (Phase 3)Ended earlyNCT01437787
What this trial is testing

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis

Who this might be right for
Hematopoietic Neoplasm
Bristol-Myers Squibb 289
Not applicableStudy completedNCT00296023
What this trial is testing

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+2 more
University of California, San Francisco 25
Testing effectiveness (Phase 2)Looking for participantsNCT06786234
What this trial is testing

Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial

Who this might be right for
Essential Thrombocythaemia
Step Pharma, SAS 50
Not applicableStudy completedNCT02953704
What this trial is testing

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

Who this might be right for
MPN (Myeloproliferative Neoplasms)
Incyte Corporation 1,469
Testing effectiveness (Phase 2)Study completedNCT00110045
What this trial is testing

Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant

Who this might be right for
Cancer
European Organisation for Research and Treatment of Cancer - EORTC 171
Early research (Phase 1)Study completedNCT00004904
What this trial is testing

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+5 more
Northwestern University
Large-scale testing (Phase 3)Study completedNCT02076815
What this trial is testing

Anagrelide Retard in Essential Thrombocythemia

Who this might be right for
Essential Thrombocythemia
AOP Orphan Pharmaceuticals AG 106
Testing effectiveness (Phase 2)Study completedNCT02125318
What this trial is testing

Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders

Who this might be right for
ThrombocytosisMyeloproliferative Neoplasms
Galena Biopharma, Inc. 18
Large-scale testing (Phase 3)Ended earlyNCT03755518
What this trial is testing

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisMyelofibrosis+1 more
Celgene 38
Testing effectiveness (Phase 2)Study completedNCT01787552
What this trial is testing

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Who this might be right for
Primary MyelofibrosisThrombocytosisEssential Thrombocythemia+7 more
Novartis Pharmaceuticals 50
Testing effectiveness (Phase 2)Ended earlyNCT01523171
What this trial is testing

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib

Who this might be right for
Hematopoietic Neoplasm
Bristol-Myers Squibb 97